Coherus Oncology, Inc. (CHRS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
31/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseCHRS / S&P -17.16% / 15.20% |
WinCHRS / S&P 61.00% / 15.00% |
LoseCHRS / S&P -122.99% / 50.40% |
| 2026-Q12/3 |
WinCHRS / S&P 19.01% / -4.33% |
WinCHRS / S&P 47.99% / 11.30% |
LoseCHRS / S&P -15.03% / 27.70% |
| 2025-Q42/3 |
LoseCHRS / S&P -13.41% / 2.65% |
WinCHRS / S&P 59.81% / 9.00% |
WinCHRS / S&P 1562.96% / 13.40% |
| 2025-Q31/3 |
WinCHRS / S&P 124.35% / 8.12% |
LoseCHRS / S&P -66.28% / 4.61% |
LoseCHRS / S&P -14733.33% / 13.45% |
| 2025-Q20/3 |
LoseCHRS / S&P -9.42% / 10.94% |
LoseCHRS / S&P -82.30% / 4.83% |
LoseCHRS / S&P -1417.14% / 10.63% |
| 2025-Q10/3 |
LoseCHRS / S&P -41.52% / -4.27% |
LoseCHRS / S&P -86.05% / 4.98% |
LoseCHRS / S&P -364.38% / 10.57% |
| 2024-Q41/3 |
WinCHRS / S&P 32.69% / 2.41% |
LoseCHRS / S&P -89.74% / 5.25% |
LoseCHRS / S&P -110.38% / 6.15% |
| 2024-Q30/3 |
LoseCHRS / S&P -39.88% / 5.89% |
LoseCHRS / S&P -47.80% / 5.89% |
LoseCHRS / S&P -98.85% / 6.11% |
| 2024-Q20/3 |
LoseCHRS / S&P -27.62% / 4.28% |
LoseCHRS / S&P -1.78% / 5.38% |
LoseCHRS / S&P -89.46% / 5.12% |
| 2024-Q11/3 |
LoseCHRS / S&P -28.23% / 10.56% |
WinCHRS / S&P 23.86% / 5.71% |
LoseCHRS / S&P -79.02% / 5.59% |
| 2023-Q41/3 |
LoseCHRS / S&P -10.96% / 11.69% |
WinCHRS / S&P 21.89% / 6.81% |
LoseCHRS / S&P -30.85% / 7.78% |
| 2023-Q30/3 |
LoseCHRS / S&P -12.41% / -3.27% |
LoseCHRS / S&P -11.71% / 7.52% |
LoseCHRS / S&P -27.02% / -5.03% |
| 2023-Q21/3 |
LoseCHRS / S&P -37.57% / 8.74% |
LoseCHRS / S&P -34.12% / 9.50% |
WinCHRS / S&P 11.78% / -8.57% |
| 2023-Q11/3 |
LoseCHRS / S&P -13.64% / 7.50% |
LoseCHRS / S&P -39.61% / 10.77% |
WinCHRS / S&P 27.94% / -15.69% |
| 2022-Q41/3 |
LoseCHRS / S&P -17.59% / 7.56% |
LoseCHRS / S&P -35.37% / 11.88% |
WinCHRS / S&P -2.34% / -17.99% |
| 2022-Q32/3 |
WinCHRS / S&P 32.73% / -4.88% |
LoseCHRS / S&P -34.25% / 13.47% |
WinCHRS / S&P 13.61% / -1.41% |
| 2022-Q21/3 |
LoseCHRS / S&P -43.92% / -16.10% |
LoseCHRS / S&P -30.03% / 13.71% |
WinCHRS / S&P 26.92% / 11.04% |
| 2022-Q11/3 |
LoseCHRS / S&P -19.11% / -4.60% |
LoseCHRS / S&P -31.41% / 15.97% |
WinCHRS / S&P 119.35% / 42.23% |
| 2021-Q40/3 |
LoseCHRS / S&P -0.68% / 11.03% |
LoseCHRS / S&P -31.37% / 15.00% |
LoseCHRS / S&P -339.13% / 96.40% |
| 2021-Q31/3 |
WinCHRS / S&P 16.20% / 0.58% |
LoseCHRS / S&P -25.68% / 10.77% |
LoseCHRS / S&P -254.15% / 69.42% |
| 2021-Q20/3 |
LoseCHRS / S&P -5.34% / 8.55% |
LoseCHRS / S&P -19.03% / 6.58% |
LoseCHRS / S&P -199.57% / 51.81% |
| 2021-Q11/3 |
LoseCHRS / S&P -15.94% / 6.17% |
WinCHRS / S&P 1.73% / -1.06% |
LoseCHRS / S&P -162.94% / 7.39% |
| 2020-Q42/3 |
LoseCHRS / S&P -5.23% / 12.15% |
WinCHRS / S&P 33.63% / -3.72% |
WinCHRS / S&P 34.17% / -33.42% |
| 2020-Q31/3 |
LoseCHRS / S&P 2.69% / 8.93% |
WinCHRS / S&P 110.69% / -2.04% |
LoseCHRS / S&P -1305.88% / -27.10% |
| 2020-Q21/3 |
LoseCHRS / S&P 10.11% / 20.54% |
WinCHRS / S&P 304.37% / -0.46% |
LoseCHRS / S&P -240.72% / -27.11% |
| 2020-Q12/3 |
WinCHRS / S&P -9.91% / -19.60% |
WinCHRS / S&P 1072.98% / 3.47% |
LoseCHRS / S&P -173.78% / -14.75% |
| 2019-Q40/3 |
LoseCHRS / S&P -11.13% / 9.07% |
LoseCHRS / S&P CHRS unavailable / 5.36% |
LoseCHRS / S&P CHRS unavailable / 2.99% |
| 2019-Q30/3 |
LoseCHRS / S&P -8.33% / 1.70% |
LoseCHRS / S&P CHRS unavailable / 5.02% |
LoseCHRS / S&P CHRS unavailable / 0.21% |
| 2019-Q21/3 |
WinCHRS / S&P 62.02% / 4.30% |
LoseCHRS / S&P CHRS unavailable / 6.64% |
LoseCHRS / S&P CHRS unavailable / 8.65% |
| 2019-Q11/3 |
WinCHRS / S&P 50.72% / 13.65% |
LoseCHRS / S&P CHRS unavailable / 8.12% |
LoseCHRS / S&P CHRS unavailable / 14.29% |
| 2018-Q40/3 |
LoseCHRS / S&P -45.15% / -13.52% |
LoseCHRS / S&P CHRS unavailable / 9.05% |
LoseCHRS / S&P CHRS unavailable / 18.23% |
| 2018-Q31/3 |
WinCHRS / S&P 17.86% / 7.71% |
LoseCHRS / S&P CHRS unavailable / 10.21% |
LoseCHRS / S&P CHRS unavailable / 19.06% |
| 2018-Q21/3 |
WinCHRS / S&P 26.70% / 3.43% |
LoseCHRS / S&P CHRS unavailable / 9.03% |
LoseCHRS / S&P CHRS unavailable / 14.46% |
| 2018-Q11/3 |
WinCHRS / S&P 25.57% / -0.76% |
LoseCHRS / S&P CHRS unavailable / 7.68% |
LoseCHRS / S&P CHRS unavailable / 12.46% |
| 2017-Q40/3 |
LoseCHRS / S&P -34.08% / 6.64% |
LoseCHRS / S&P CHRS unavailable / 7.03% |
LoseCHRS / S&P CHRS unavailable / 13.82% |
| 2017-Q30/3 |
LoseCHRS / S&P -6.97% / 4.48% |
LoseCHRS / S&P CHRS unavailable / 5.68% |
LoseCHRS / S&P CHRS unavailable / 17.57% |
| 2017-Q20/3 |
LoseCHRS / S&P -32.15% / 3.09% |
LoseCHRS / S&P CHRS unavailable / 4.83% |
LoseCHRS / S&P CHRS unavailable / 17.74% |
| 2017-Q10/3 |
LoseCHRS / S&P -24.87% / 6.07% |
LoseCHRS / S&P CHRS unavailable / 3.67% |
LoseCHRS / S&P CHRS unavailable / 13.32% |
| 2016-Q41/3 |
WinCHRS / S&P 5.12% / 3.82% |
LoseCHRS / S&P CHRS unavailable / 2.09% |
LoseCHRS / S&P CHRS unavailable / 7.05% |
| 2016-Q31/3 |
WinCHRS / S&P 58.56% / 3.85% |
LoseCHRS / S&P CHRS unavailable / 0.20% |
LoseCHRS / S&P CHRS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CHRS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 25.86% | 20.78% |
| Annualized return | 25.86% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CHRS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.94% | 83.14% |
| Annualized return | -38.14% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CHRS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.13% | 319.30% |
| Annualized return | -26.08% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |